Skip to content

Longitudinal Study of Gene Expression in the Human Placenta During First-trimester and Full-term Pregnancy at the Single Cell Level

Cellular Transcriptomic Trajectory of the Human Placenta During Pregnancy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06427408
Acronym
VilliRNAseq
Enrollment
100
Registered
2024-05-23
Start date
2026-03-25
Completion date
2029-02-01
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Related

Keywords

Placenta, Single nuclei RNA-seq, Preeclampsia, Pregnancy outcomes

Brief summary

The single nucleus RNA-seq approach allows the placental transcriptome to be analyzed from nuclei, thus preserving the integrity of placental syncytium. This approach is feasible on small fragments of villi and offers for the first time the possibility to consider the characterization of gene expression within the structural unit of the human placenta during pregnancy (at the 1st trimester and childbirth)

Detailed description

Chorionic villus biopsies are routinely performed between 11SA and 15SA at the Fetal Medicine Unit́ of the Port-Royal Maternity Hospital (CPDPN Cochin) after the patient has signed an information and consent form for the genetic analysis. The patient will be asked to participate to the VilliRNAseq project and will sign the consent form of the study. After the cytogeneticist observation, a villi fragment will be snap-frozen in liquid nitrogen and stored at -80°C until use. Each patient sampled in the first trimester is followed until the end of the pregnancy. At delivery, cesarean section or vaginal delivery, a placental sample will be snap-frozen in liquid nitrogen and stored at -80°C until use. Isolation, sorting and encapsidation of nuclei, RNA libraries preparation and sequencing will be carried out using 10x Genomics technology. State-of-the-art computational analyses to decipher trajectories and cell-to-cell communications.

Interventions

Placental transcriptomic analysis

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 to 50 * Progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea * Patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics * Patient scheduled for delivery at Port-Royal Maternity Hospital

Exclusion criteria

* Minor patient * Multiple pregnancy * Patient's objection * Without health insurance * Patient under guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
Analysis of the cellular transcriptomic trajectory of the human placentaDay 0Sequencing data will be analysed at the Institut Cochin, cell trajectories will be modelled and intracellular communications will be inferred

Secondary

MeasureTime frameDescription
Collection of placental samplesDay 0
Identification of early markers of pregnancy complicationsUntil at ChildbirthPre-eclampsia, growth retardation in utero, delivery before 37 SA

Countries

France

Contacts

CONTACTVassilis TSATSARIS, MD PHD
vassilis.tsatsaris@aphp.fr00331 58 41 38 71
CONTACTMarie BENHAMMANI-GODARD
marie.godard@aphp.fr0033158411190
STUDY_DIRECTORCéline MÉHATS, PHD

Institut National de la Santé Et de la Recherche Médicale, France

PRINCIPAL_INVESTIGATORHélène COLLINOT, MD

APHP

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026